Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2015 | The Trials Acceleration Programme by Leukaemia & Lymphoma Research

Charles Craddock • 12 Jun 2015
EHA 2015
General

At the 20th Congress of the European Hematology Association (EHA), Charles Craddock, FRCPath, FRCP, DPhil, BMBCh, of the University of Birmingham, Birmingham, UK, discusses the Trials Acceleration Programme (TAP) initiative by Leukaemia & Lymphoma Research. TAP aims to accelerate the clinical development of new therapies for patients with blood cancer through the creation of a network of leading treatment centers around the UK.

More from Charles Craddock

2:14
Addressing the high rate of disease relapse following alloSCT in patients with AML
Charles Craddock • 10 Dec 2023
1:32
Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock • 10 Dec 2023
1:22
The UK Impact Transplant Trials Network: a national strategy to accelerate delivery of alloSCT RCTs
Charles Craddock • 10 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals